A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

A Phase 2, Randomized, Active-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of LBL-007 in Combination With Tislelizumab Plus Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

This is a randomized, open-label study to compare how well LBL-007 works in combination with tislelizumab and chemotherapy versus tislelizumab and chemotherapy when given as the first-line treatment in participants with inoperable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC).

Inclusion Criteria:

• Able to provide written informed consent and can agree to comply with the study requirements.
• Participants with metastatic ESCC or unresectable, locally advanced ESCC.
• Histologically confirmed diagnosis of ESCC.
• Can provide a tumor sample.
• At least 1 measurable lesion as defined by RECIST v1.1.
• Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.

Exclusion Criteria:

• Prior treatment for advanced or metastatic ESCC within the past 6 months
• Locally advanced ESCC that is either resectable or potentially curable with definitive chemoradiation treatment per local investigator
• Palliative radiation treatment for ESCC within the past 4 weeks
• Participants with an esophageal/bronchial or esophageal/aorta fistula
• Prior treatment with programmed cell death protein-1 (PD-1) or other immune-oncological drugs

Note: Other protocol defined Inclusion/Exclusion criteria may apply.